Covid-19 Epidemic on Acute Stroke Management

NCT04370197 | Unknown

• 1 other identifier: 7826
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

The Covid-19 pandemic is a pandemic of an emerging infectious disease, coronavirus 2019 (Covid-19), caused by the coronavirus SARS-CoV-2. It appears in November 2019 in the city of Wuhan, China, and spreads worldwide from February 2020. The first cases of infection in France were confirmed on 24 January 2020. As of April 14, 103,573 cases of infection were confirmed, 32,292 hospitalized cases, including 6,730 in intensive care, with 15,729 deaths recorded1. The most affected regions are Ile de France and the Grand Est (in particular the Haut-Rhin department). Containment of the entire French population was introduced on 17 March, with the aim of reducing the spread of the virus and relieving the burden on the health system, particularly the intensive care units. This unprecedented health crisis, as well as the social containment measures in themselves, has repercussions on other acute medical pthologies, not directly related to the viral infection. It appears that the number of patients treated for acute stroke has suddenly declined since the beginning of the epidemic. However, it is not clear whether it is the incidence of stroke that has declined or simply the proportion of patients presenting within the time frame that allows for treatment in the acute phase (by thrombolysis or thrombectomy).

Conditions

Stroke, Acute

Keywords

STROKE , Acute; Covid-19; SARS-COV-2; Mechanical thrombectomy; Thrombolysis

Outcome Measures

Primary Outcomes (1)

• Study of the effect of pandemic covid-19 on the management of stroke patients

  1 month

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult stroke patients

You may qualify if:

• Adult patient
• Stroke Patients
• Patient who agreed to participate in this study

You may not qualify if:

• \- Refusal to participate in this study

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Neuroradiologie Interventionnelle

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Stroke; COVID-19

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Rémy BEAUJEUX, MD, PhD

CONTACT

33 3 88 12 78 71; remy.beaujeux@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR

CONTACT

33 3 88 11 66 90; said.chayer@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 29, 2020
• First Posted: April 30, 2020
• Study Start: March 3, 2020
• Primary Completion: April 30, 2020
• Study Completion: April 30, 2020
• Last Updated: April 30, 2020

Record last verified: 2020-04

Locations

FR (1)